Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO)

Historical Holders from Q4 2017 to Q3 2025

Symbol
SPRO on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
55.7M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
11.3M
Holdings value
$21.3M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
47
Number of buys
25
Number of sells
-17
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GSK plc 16.4% $6.71M 9.19M GSK PLC 27 Mar 2025
Anson Funds Management LP 2.9% $4.59M 1.62M Anson Funds Management LP 30 Jun 2025

Institutional Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 11.3M $21.3M -$925K $1.88 47
2025 Q2 11.1M $32.1M -$7.95M $2.90 44
2025 Q1 15.1M $10.9M -$477K $0.72 38
2024 Q4 15.7M $16.1M +$401K $1.03 50
2024 Q3 12.3M $16.5M -$2.02M $1.34 46
2024 Q2 13.9M $18M +$23.1K $1.30 47
2024 Q1 13.8M $23.7M -$10.7K $1.72 54
2023 Q4 13.4M $19.6M +$254K $1.47 46
2023 Q3 14.2M $17.2M -$231K $1.21 53
2023 Q2 14.4M $20.8M +$225K $1.45 56
2023 Q1 14.2M $20.6M -$6.71K $1.45 46
2022 Q4 14.2M $24.6M -$11.5M $1.73 57
2022 Q3 19.9M $39.7M +$135K $2.00 61
2022 Q2 20.9M $15.5M -$13.7M $0.74 60
2022 Q1 20.2M $176M +$3.32M $8.70 96
2021 Q4 19.8M $317M +$1.75M $16.01 82
2021 Q3 18.4M $338M +$16.5M $18.41 87
2021 Q2 16.1M $225M -$15.1M $13.96 82
2021 Q1 18.5M $273M +$11.2M $14.72 89
2020 Q4 19.1M $370M +$23.9M $19.39 87
2020 Q3 16.8M $187M +$55.4M $11.16 77
2020 Q2 11.8M $159M +$6.8M $13.53 76
2020 Q1 11.5M $93.2M +$5.36M $8.08 60
2019 Q4 10.8M $104M +$4.18M $9.61 61
2019 Q3 10.4M $110M -$2.91M $10.60 59
2019 Q2 10.6M $122M +$15.8M $11.51 60
2019 Q1 9.27M $119M +$3.62M $12.81 53
2018 Q4 9.1M $56M -$16.9M $6.15 50
2018 Q3 10.7M $113M +$24.5M $10.51 51
2018 Q2 8.12M $119M +$30.5K $14.67 42
2018 Q1 7.7M $110M -$578K $14.25 34
2017 Q4 7.76M $91.2M +$91M $11.75 36